Day: March 20, 2025

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus’ field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collaboration with Albaugh LLC and RTDC Corporation Limited continues to strengthen weed management solutions pipeline as Cibus continues development with four major seed company customers Sclerotinia (White Mold) resistance trait development continues progress with fourth mode of action successfully edited in Canola demonstrating progress towards the development of a durable trait comprising multiple modes of...

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update. “We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our clinical trials reinforces our confidence in the potential of trem-cel and VCAR33 to transform the treatment landscape,” said Dr. Robert Ang,...

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

– Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer – – Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer – – Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial – – Named industry veteran Dr. Igor Matushansky as Chief Medical Officer – – Cash runway extended into 2026 – CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking...

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates. “2024 was a year of significant clinical progress...

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009 (Tambiciclib) in r/r AML – Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – – Raised $25 Million in Gross Proceeds in a Registered Direct Offering in January 2025 – NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31,...

New York Mortgage Trust Declares First Quarter 2025 Common Stock Dividend of $0.20 Per Share, and Preferred Stock Dividends

Written by Customer Service on March 20, 2025. Posted in Dividend Reports And Estimates.

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.20 per share on shares of its common stock for the quarter ending March 31, 2025. The dividend will be payable on April 28, 2025 to common stockholders of record as of the close of business on March 31, 2025. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series D Preferred Stock”), 7.875% Series E Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series E Preferred Stock”), 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series F Preferred Stock”) and 7.000% Series G Cumulative Redeemable...

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer Advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030 Discontinuing further internal clinical development of vobra duo; exploring potential partnering Cash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026 Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of...

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. “Throughout 2024, we shared multiple data updates from our two lead anti-cancer medicines, NUC-7738 and NUC-3373,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer....

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2024. “Since our founding, Vaxart has been on a mission to transform global health with the goal of pioneering oral pill vaccines that can provide protection against common viral diseases safely and effectively,” said Steven Lo,...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2024 operating and financial results and reviewed recent business...

Day: March 20, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals